Zenas BioPharma (NASDAQ: ZBIO) revenue
Zenas BioPharma reported revenue of $10.0m for fiscal 2025, 100.0% more than in fiscal 2024 ($5.0m). Since fiscal 2023 its revenue has fallen by 80.0%, an average decline of 55.3% a year.
Zenas BioPharma's best year of the last 3 was fiscal 2023. The biggest drop was in fiscal 2024, −90.0%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $10.0m | +100.0% | −$383.1m | −3,830.6% |
| 2024 | $5.0m | −90.0% | −$163.9m | −3,277.8% |
| 2023 | $50.0m | — | −$37.1m | −74.3% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Zenas BioPharma revenue compared with its sector
By revenue for its latest fiscal year, Zenas BioPharma ranks 368th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Zenas BioPharma, 100.0%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 366th | Crescent Biopharma | $10.8m | — |
| 367th | Janux Therapeutics | $10.0m | −5.6% |
| 368th | Zenas BioPharma | $10.0m | 100.0% |
| 369th | Taysha Gene Therapies | $9.8m | 17.3% |
| 370th | Precigen | $9.7m | 146.7% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Zenas BioPharma
- How much revenue did Zenas BioPharma make in fiscal 2025?
- Zenas BioPharma reported revenue of $10.0m for fiscal 2025, compared with $5.0m in fiscal 2024.
- How much has the revenue of Zenas BioPharma fallen?
- Between fiscal 2023 and fiscal 2025 it went from $50.0m to $10.0m: 80.0% less, an average decline of 55.3% a year.
- What was the best year for revenue at Zenas BioPharma?
- Of its last 3 fiscal years, fiscal 2023, with $50.0m.
- Where does Zenas BioPharma rank in its sector by revenue?
- It ranks 368th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Zenas BioPharma come from?
- From the annual report (Form 10-K) that Zenas BioPharma files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Zenas BioPharma files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023. More on Zenas BioPharma: the Zenas BioPharma page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.